Spyre Therapeutics, Inc. (SYRE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 29, 2025, discloses the results of Spyre Therapeutics, Inc.'s Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol "SYRE."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected three Class III directors to serve until the 2028 Annual Meeting.
- Peter Harwin: 38,196,060 For; 7,977,323 Withheld.
- Michael Henderson, M.D.: 45,441,918 For; 731,465 Withheld.
- Sandra Milligan, M.D., J.D.: 37,612,795 For; 8,560,588 Withheld.
- Proposal 2 (Executive Compensation): Stockholders approved the non-binding advisory vote on executive compensation.
- Results: 42,930,720 For; 3,144,040 Against; 98,623 Abstain.
- Proposal 3 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025.
- Results: 49,227,863 For; 57,123 Against; 8,829 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Peter Harwin, Michael Henderson, and Sandra Milligan) through the 2028 Annual Meeting.
- Confirm the ratification of KPMG LLP as the auditor for the fiscal year ending December 31, 2025.
- Note the significant number of broker non-votes (3,120,432) recorded for the director elections, which may indicate shares held in street name where instructions were not received.
- Review the definitive proxy statement filed on April 14, 2025, for detailed background on the proposals and executive compensation specifics.